XEIA Venture Partners
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at XEIA Venture Partners.
Key people at XEIA Venture Partners.
Key people at XEIA Venture Partners.
XEIA Venture Partners is a San Francisco-based early-stage venture capital firm focused on investing in startups that drive what they call "Human 3" — an era of exponential human flourishing. Their portfolio spans life sciences, artificial intelligence (AI), hardware, software, deep tech, and health tech, often combining these fields in innovative ways that defy conventional categories. XEIA’s mission centers on advancing health, wellbeing, and human performance through cutting-edge technologies and scientific breakthroughs, positioning them as a key player in the intersection of technology and life sciences[2][3][4].
Founded by key partners including Brom Rector and Sam Tabone, XEIA Venture Partners emerged with a vision to back transformative early-stage companies that push the boundaries of human potential. The firm is relatively recent, with its current fund launched in April 2025. The founding team brings deep expertise in AI, medicinal chemistry, psychoactive pharmacology, and neuroscience, including leadership roles such as directing MIT’s Aging Brain Initiative. This scientific and technical foundation informs their investment focus and strategy, emphasizing breakthrough innovation in health and technology[2][4].
XEIA is riding the wave of convergence between AI, life sciences, and health technology, a trend accelerating due to advances in machine learning, biotechnology, and hardware innovation. The timing is critical as society increasingly demands solutions for aging, mental health, and human performance enhancement. By investing at this intersection, XEIA influences the broader ecosystem by enabling startups that could redefine healthcare, wellness, and human capabilities, contributing to a new epoch of human flourishing[3][4].
Looking ahead, XEIA Venture Partners is poised to expand its influence as the "Human 3" concept gains traction. Trends such as AI-driven drug discovery, personalized medicine, and neurotechnology will likely shape their investment journey. As their portfolio matures, XEIA could become a pivotal catalyst for startups that transform health and human potential, reinforcing their role at the forefront of this emerging technological and scientific frontier. Their unique blend of scientific expertise and venture capital acumen positions them well to capitalize on and shape the future of human-centered innovation[3][4].
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2022 | HealingMaps | $1.0M Seed | — | Ambria Capital, Jenny Friedman, Vinay Hiremath |
| Sep 1, 2021 | incident.io | $6.0M Seed | — | Alt Capital, Ambria Capital, Crane Venture Partners, Eka Ventures, Felix Capital, Founders Fund, General Catalyst, Hanabi Capital, Index Ventures, Jenny Friedman, MMC Ventures, Saga, ShareBear Capital, Starship Ventures, Adam Guild, Dylan Field, Sam Altman, Shane Curran |
